SARS-CoV-2: vaccinology and emerging therapeutics; challenges and future developments.

ABSTRACT

As SARS-CoV-2 emerge, variants such as Omicron (B.1.1.529), Delta (B.1.617.2), and those from the United Kingdom (B.1.1.7), South Africa (B.1.351), Brazil (P.1) and India (B.1.6.17 lineage) have raised concerns of the reduced neutralising ability of antibodies and increased ability to evade the current six approved COVID-19 vaccine candidates. This viewpoint advocates for countries to conduct prior efficacy studies before they embark on mass vaccination and addresses the role of nanoparticles as carrier vehicles for these vaccines with a view to explore the present challenges and forge a path for a stronger and more viable future for the development of vaccines for SARS-CoV-2 and future pandemics. We also look at the emerging prophylactics and therapeutics in the light of ongoing cases of severe and critical COVID-19.